Health Canada authorizes elinzanetant (brand name Lynkuet) to treat moderate to severe hot flashes and night sweats in patients with breast cancer. The approval covers symptom relief for people whose breast cancer treatment leads to menopausal symptoms, including those experiencing sleep disruption from night sweats.
Both outlets report that elinzanetant was previously approved in July 2025 for treating hot flashes and night sweats in women undergoing menopause. Health Canada’s latest decision follows additional evidence reviewed by the department that the drug is effective for breast cancer patients receiving estrogen-suppressing therapies, which can induce menopausal conditions.
While the outlets closely align on what is being approved and the patient group, they frame the rationale slightly differently: one emphasizes the timeline of the earlier menopause indication, while the other highlights the mechanism of estrogen suppression by breast cancer treatment. Neither report indicates that the drug is intended to treat cancer itself, focusing instead on managing related menopausal symptoms.
